© 2021 BioMarin. All rights reserved.

BioMarin to Host Fourth Quarter and Full Year 2006 Financial Results Conference Call and Webcast on Thursday, February 22 at 5:00 p.m. ET (23:00 CET)
Feb 15, 2007
PRNewswire-FirstCall
NOVATO, Calif.

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 22, at 5:00 p.m. ET (23:00 CET) to discuss fourth quarter and full year 2006 financial results.

   What:     BioMarin Fourth Quarter and Full Year 2006 Earnings Call and
             Webcast
   When:     Thursday, February 22, 2007 at 5:00 p.m. ET (23:00 CET)
             U.S. / Canada Dial-in Number:  800.901.5217
             International Dial-in Number:  617.786.2964
             Participant Code: 35915200
             Replay Dial-in Number: 888.286.8010
             Replay International Dial-in Number: 617.801.6888
             Replay Code: 94899251

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for at least one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Phenoptin(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of poorly controlled hypertension and peripheral arterial disease. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

NOTE: Naglazyme(R) is a registered trademark of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Contact: Eugenia Shen of BioMarin Pharmaceutical Inc., +1-415-506-6570.

FCMN Contact: eshen@bmrn.com

SOURCE: BioMarin Pharmaceutical Inc.

CONTACT: Eugenia Shen of BioMarin Pharmaceutical Inc., +1-415-506-6570